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Abstract
Background: The objective of this study was to assess side effects and satisfaction about OsteoCalVitFort (500 mg
calcium and 400 I.U. of vitamin D3) usage.
Methods: A total 186 people were participated with range age from 18 to 65 years old. Each participant received 1
pack that contains 60 OsteoCalVitFort tablet and used two tablet OsteoCalVitFort daily (1 tablet after breakfast and
1 after dinner). By a phone call, side effects and satisfaction about OsteoCalVitFort were assessed.
Results: The rate of constipating (8.0 %) and bloating (12.5 %) were decreased significantly after OsteoCalVitFort
supplement intake (1.2 %, and 0.6 %, respectively). Similar results were observed in metallic taste in mouth, tiredness,
weakness, loss of appetite, bone/muscle pain and mental/mood change after Calcium Vitamin D3 supplementation
intake. Totally, 94 % of patients were satisfied about OsteoCalVitFort usage.
Conclusion: The results of the research indicate despite the high quality of OsteoCalVitFort supplement, there are no
side effects which have been seen in other supplements.
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Background
There is little debate about calcium needs during life-
span for optimizing health in health of bone and out of
bone [1, 2]. Many people are avoid or limit dairy prod-
ucts because of lactase intolerant, then they have no
choice but to eat supplement [3–5]. Calcium supple-
ments cause few, if any, side effects, unfortunately [6].
Side effects can sometimes occur, including gas, consti-
pation, bloating, nausea/vomiting, loss of appetite,
mental/mood changes, and bone/muscle pain. Vitamin
D3 is used to facilitate absorption of the calcium in the
gut [7, 8], and to facilitate calcium incorporation in the
bones. Low vitamin D levels are associated with impair-
ment of the active absorption of calcium [9]. Fortified Vita-
min D3 with calcium without gastrointestinal side effect is
a greatest effective factor to prevent bone loss [10–12].
OsteoCalVitFort seems more potent form of other Vita-
min D and Calcium supplement (500 mg calcium and 400
I.U. of vitamin D3). The aim of this study was to evaluate
side effects and satisfaction level of OsteoCalVitFort
among people who consumed calcium supplement.
Method
This study was single arm, prospective study that was
done on 186 people who consumed Calcium supple-
ment. Inclusion criteria were participants with age be-
tween 45 to 70 years old, in good health. Exclusion
criteria were presence of any chronic illness such as
chronic hepatic diseases, chronic kidney diseases, car-
diac, hematologic, gastrointestinal, psychological prob-
lems, any diagnosed malignancy, history of active
inflammatory illness, breast feeding, pregnancy, and
history of kidney stone, hyperparathyroidism. After
complete explanation of the study aim, informed con-
sent from each participant was gathered.
Each participant received 1 pack that contains 60
OsteoCalVitFort tablet and used two tablet OsteoCalVit-
Fort daily (1 tablet after breakfast and 1 after dinner).
Side effects and satisfaction about OsteoCalVitFort
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consumption were assessed through case report form
(CRF) by phone call.
Ethical considerations
This study was proposed and approved by the Ethics-in-
Research Commission of Endocrinology and Metabolism
Research Institute, Tehran University of Medical Sciences.
Also, it has been registered on the Iranian clinical trial
registration (www.irct.ir) as IRCT201312031414N30.
Statistical analysis
Data were analyzed by using the SPSS version 16 for Win-
dows (SPSS Inc., Chicago, IL). The one–way ANOVA was
used to determine the statistical significance of differences
between the values for this study. Values of p < 0.05 were
considered statistically significant.
Result
The samples were composed of 166 (89.2 %) women and
20 (10.8 %) men with mean age of 52.78 ± 13.21, and
49.0 ± 16.50, respectively. The rate of low illiterate was
32.8 %, of illiterate was 1.07 %, of diploma was 36.2 %,
and of high was 20.3 %.
The rate of constipating (8.0 %) and bloating (12.5 %)
were decreased significantly after OsteoCalVitFort sup-
plement intake (1.2 %, and 0.6 %, respectively). The per-
cent of metallic taste in mouth at the first study (8.0 %)
was significantly reduced compared to end of study
(0.6 %). Significantly, the rate of tiredness (9.7 %), weak-
ness (5.1 %), and loss of appetite (1.7 %) were decreased
compared to OsteoCalVitFort supplement intake (0.6 %,
1.2 %, and 0.6 %, respectively). Significant decrease in
bone/muscle pain changes was observed at the end of
study (Table 1).
Totally, 94 % of participants were satisfaction with
using OsteoCalVitFort supplement.
Discussion
Osteoporosis is major medical issues at the community
level and can be lead to excessive [13–17]. A study in
Iran has shown that Osteoporosis is an important health
challenge and increases with age and changes in life style
[18]. Dietary calcium is critical for the growth and devel-
opment of the body skeleton and it seems plays a vital
role in the prevention of osteoporosis [19]. Many people
are avoided dairy products because of lactase intolerant.
In these situations, calcium supplements can help them
meet their calcium requirements [5].
OsteoCalVitFort contain high amounts of vitamin D
with calcium. The role of vitamin D is bone preservation
by improving the absorption of calcium from food and
reduce fractures in older [18]. Most people who received
Calcium, Vitamin D supplementation meet the gastro-
intestinal side effects and they are not satisfied for this
obligatory administered by their physician. After con-
sume of OsteoCalVitFort significant positive impact in
constipating, bloating, metallic taste in mouth, thirst,
tiredness, weakness, loss of appetite, and bone/muscle
pain were observed.
The present study showed satisfaction level of Osteo-
CalVitFort intakes about 94 % of patients was satisfied.
Consumers have multiple brands from which to choose
but few assurances that the products are of high quality.
Intake of OsteoCalVitFort can lead to Compensation
amounts of Calcium and vitamin D. This supplement
has no side effects. Satisfaction is a behavioral perspec-
tive on product consumer and it is too important that
quality and satisfaction to be in a line.
Conclusion
The results of this survey have shown despite the high
quality of OsteoCalVitFort supplement, there are not
side effects which have been seen in other supplements.
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Table 1 Comparison of the previous and next effects of taking
OsteoCalVitFort
Side effects Before Practice After Practice P-value
Nausea/Vomiting 2.3* 4.9 0.22
Constipating 8.0 1.2 0.003
Gas 6.8 2.5 0.146
Diarrhea 0.6 1.2 1.000
Bloating 12.5 0.6 0.000
Loss of appetite 1.7 0.6 0.04
Dry Mouth 8.5 3.1 0.07
Metallic taste in mouth 8.0 0.6 0.001
Increased thirst/urine 6.8 1.2 0.02
Tiredness 9.7 0.6 0.001
Weakness 5.1 1.2 0.03
Headache 7.4 3.1 0.057
Bone/muscle pain 12.5 1.2 0.000
*%, P-value <0.05
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